Everything on Pharma & Biotech

The valuation of Eli Lilly has been challenged by analyst skepticism regarding the sustainable size of the weight-loss drug market. This indicates a broader market reassessment of high-growth pharmaceutical narratives.

Impact: Investors may demand stronger evidence of market penetration and pricing power from biotech companies, leading to increased volatility in high-multiple growth stocks.

— from German Wealth Erosion and Schufa Score Overhaul · Alles auf Aktien – Die täglichen Finanzen-News· Mar 18, 2026